A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

Two Street analysts weigh in on Amgen's phase 2 MariTide data, saying that they would like to see additional details on the ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...